Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
<strong>Background</strong> The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified. <br> <strong>Methods</strong> We performed a meta-analysis of published large (>500 participants/arm)...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2021
|
| _version_ | 1797082449758388224 |
|---|---|
| author | Staplin, N Roddick, AJ Emberson, J Reith, C Riding, A Wonnacott, A Kuverji, A Bhandari, S Baigent, C Haynes, R Herrington, WG |
| author_facet | Staplin, N Roddick, AJ Emberson, J Reith, C Riding, A Wonnacott, A Kuverji, A Bhandari, S Baigent, C Haynes, R Herrington, WG |
| author_sort | Staplin, N |
| collection | OXFORD |
| description | <strong>Background</strong>
The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified.
<br>
<strong>Methods</strong>
We performed a meta-analysis of published large (>500 participants/arm) placebo-controlled SGLT-2 inhibitor trials after systematically searching MEDLINE and Embase databases from inception to 28th August 2021 (PROSPERO 2021 CRD42021240468).
<br>
<strong>Findings</strong>
Four heart failure trials (n=15,684 participants), four trials in type 2 diabetes mellitus at high atherosclerotic cardiovascular risk (n=42,568), and three trials in chronic kidney disease (n=19,289) were included. Relative risks (RRs) for all cardiovascular, renal and safety outcomes were broadly similar across these three patient groups, and between people with or without diabetes. Overall, compared to placebo, allocation to SGLT-2 inhibition reduced risk of hospitalization for heart failure or cardiovascular death by 23% (RR=0.77, 95%CI 0.73-0.80; n=6658), cardiovascular death by 14% (0.86, 0.81-0.92; n=3962), major adverse cardiovascular events by 11% (0.89, 0.84-0.94; n=5703), kidney disease progression by 36% (0.64, 0.59-0.70; n=2275), acute kidney injury by 30% (0.70, 0.62-0.79; n=1013 events) and severe hypoglycaemia by 13% (0.87, 0.79-0.97; n=1484). There was no effect of SGLT-2 inhibition on risk of non-cardiovascular death (0.93, 0.86-1.01; n=2226), but a net 12% reduction in all-cause mortality remained evident (0.88, 0.84-0.93; n=6188). However, the risk of ketoacidosis was 2-times higher among those allocated SGLT-2 inhibitors compared to placebo (2.03, 1.41-2.93; n=159; absolute excess in people with diabetes ∼0.3/1000 patient years). A small increased risk of urinary tract infection was evident (1.07, 1.02-1.13; n=5384) alongside a known increased risk of mycotic genital infections. Overall, risk of lower limb amputations was increased by 16% (1.16, 1.02-1.31; n=1074), but this risk was largely driven by a single outlying trial (CANVAS).
<br>
<strong>Interpretations</strong>
The relative effects of SGLT-2 inhibition on key safety and efficacy outcomes are consistent across the different studied groups of patient. Consequently, absolute benefits and harms are determined by the absolute baseline risk of particular outcomes, with absolute benefits on mortality and on non-fatal serious cardiac/renal outcomes substantially exceeding the risks of amputation and ketoacidosis in the main patient groups studied to date.
<br>
<strong>Funding</strong>
MRC-UK & KRUK. |
| first_indexed | 2024-03-07T01:28:16Z |
| format | Journal article |
| id | oxford-uuid:92b557b0-3298-4b3c-9ac5-6e2e38f39e1b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:28:16Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:92b557b0-3298-4b3c-9ac5-6e2e38f39e1b2022-03-26T23:27:30ZNet effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trialsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:92b557b0-3298-4b3c-9ac5-6e2e38f39e1bEnglishSymplectic ElementsElsevier2021Staplin, NRoddick, AJEmberson, JReith, CRiding, AWonnacott, AKuverji, ABhandari, SBaigent, CHaynes, RHerrington, WG<strong>Background</strong> The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified. <br> <strong>Methods</strong> We performed a meta-analysis of published large (>500 participants/arm) placebo-controlled SGLT-2 inhibitor trials after systematically searching MEDLINE and Embase databases from inception to 28th August 2021 (PROSPERO 2021 CRD42021240468). <br> <strong>Findings</strong> Four heart failure trials (n=15,684 participants), four trials in type 2 diabetes mellitus at high atherosclerotic cardiovascular risk (n=42,568), and three trials in chronic kidney disease (n=19,289) were included. Relative risks (RRs) for all cardiovascular, renal and safety outcomes were broadly similar across these three patient groups, and between people with or without diabetes. Overall, compared to placebo, allocation to SGLT-2 inhibition reduced risk of hospitalization for heart failure or cardiovascular death by 23% (RR=0.77, 95%CI 0.73-0.80; n=6658), cardiovascular death by 14% (0.86, 0.81-0.92; n=3962), major adverse cardiovascular events by 11% (0.89, 0.84-0.94; n=5703), kidney disease progression by 36% (0.64, 0.59-0.70; n=2275), acute kidney injury by 30% (0.70, 0.62-0.79; n=1013 events) and severe hypoglycaemia by 13% (0.87, 0.79-0.97; n=1484). There was no effect of SGLT-2 inhibition on risk of non-cardiovascular death (0.93, 0.86-1.01; n=2226), but a net 12% reduction in all-cause mortality remained evident (0.88, 0.84-0.93; n=6188). However, the risk of ketoacidosis was 2-times higher among those allocated SGLT-2 inhibitors compared to placebo (2.03, 1.41-2.93; n=159; absolute excess in people with diabetes ∼0.3/1000 patient years). A small increased risk of urinary tract infection was evident (1.07, 1.02-1.13; n=5384) alongside a known increased risk of mycotic genital infections. Overall, risk of lower limb amputations was increased by 16% (1.16, 1.02-1.31; n=1074), but this risk was largely driven by a single outlying trial (CANVAS). <br> <strong>Interpretations</strong> The relative effects of SGLT-2 inhibition on key safety and efficacy outcomes are consistent across the different studied groups of patient. Consequently, absolute benefits and harms are determined by the absolute baseline risk of particular outcomes, with absolute benefits on mortality and on non-fatal serious cardiac/renal outcomes substantially exceeding the risks of amputation and ketoacidosis in the main patient groups studied to date. <br> <strong>Funding</strong> MRC-UK & KRUK. |
| spellingShingle | Staplin, N Roddick, AJ Emberson, J Reith, C Riding, A Wonnacott, A Kuverji, A Bhandari, S Baigent, C Haynes, R Herrington, WG Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials |
| title | Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials |
| title_full | Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials |
| title_fullStr | Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials |
| title_full_unstemmed | Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials |
| title_short | Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials |
| title_sort | net effects of sodium glucose co transporter 2 inhibition in different patient groups a meta analysis of large placebo controlled randomized trials |
| work_keys_str_mv | AT staplinn neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT roddickaj neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT embersonj neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT reithc neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT ridinga neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT wonnacotta neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT kuverjia neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT bhandaris neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT baigentc neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT haynesr neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials AT herringtonwg neteffectsofsodiumglucosecotransporter2inhibitionindifferentpatientgroupsametaanalysisoflargeplacebocontrolledrandomizedtrials |